Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey.

AIMS In atrial fibrillation (AF) cardioversion is the cornerstone of the rhythm management strategy despite the lack of contemporary data on acute and long-term success. We aim to describe present-day cardioversion of AF and identify characteristics associated with immediate and long-term outcome. METHODS AND RESULTS Based on the 5333 AF patients enrolled in the multi-centre prospective Euro Heart Survey on AF we selected the 1801 patients undergoing cardioversion at enrolment. Sinus rhythm (SR) was restored in 630 of 712 (88%), 458 of 643 (71%), and 333 of 446 (75%) (P< 0.001) of the electrical (ECV), intravenous (ivCCV), and oral (oCCV) chemical cardioversions, respectively, at the cost of few (4.2%) major complications. In multivariate analysis, absence of chronic obstructive pulmonary disease (COPD) (P< 0.001), presence of paroxysmal AF (PAF) (P= 0.013), and use of biphasic waveform (P= 0.018) were predictors of successful ECV. For ivCCV PAF (P< 0.001), absence of valvular heart disease (P= 0.004), and heart failure (P= 0.009), the presence of hypertension (P= 0.018) and coronary artery disease (P= 0.007) were predictive. Success of oCCV was driven by PAF (P< 0.001) and a smaller left atrial dimension (P= 0.001). At 1-year follow-up 893 of 1271 (70%) patients were in SR. Multivariate analysis revealed PAF (P< 0.001), shorter total AF history (P< 0.001), continuous use of Class Ic drugs or amiodarone during follow-up (P< 0.001), absence of COPD (P= 0.003), younger age (P= 0.004), and smaller left atrial dimension (P= 0.005) as independent predictors of SR at 1-year follow-up. CONCLUSIONS Contemporary cardioversion of AF is routinely successfully and safely performed with a high proportion of patients in SR at 1-year follow-up.

[1]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  A. Capucci,et al.  Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment , 2010, Heart.

[3]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[4]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[5]  Massimo Santini,et al.  Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. , 2008, European heart journal.

[6]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .

[7]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[8]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[9]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[10]  Kapil R. Desai Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[11]  G. Breithardt,et al.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). , 2005, European heart journal.

[12]  D. Reda,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[13]  Medicina Nei Secoli La Redazione No Abstract Available , 2005 .

[14]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. , 2004, The New England journal of medicine.

[15]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[16]  G. Heinze,et al.  Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. , 2004, European heart journal.

[17]  H. Thode,et al.  Electrical cardioversion of emergency department patients with atrial fibrillation. , 2004, Annals of emergency medicine.

[18]  N. Rehnqvist,et al.  Sotalol versus quinidine in the maintenance of sinus rhythm after direct current conversion of atrial fibrillation , 1990, Cardiovascular Drugs and Therapy.

[19]  Haran Burri,et al.  Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. , 2003, Journal of the American College of Cardiology.

[20]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[21]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[22]  G. Breithardt,et al.  Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial , 2002, The Lancet.

[23]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[24]  C. M. Hart,et al.  Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. , 2002, Journal of the American College of Cardiology.

[25]  R. Kerber,et al.  Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. , 2002, Journal of the American College of Cardiology.

[26]  I. V. Van Gelder,et al.  Rate control versus electrical cardioversion for atrial fibrillation: A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design. , 2002, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[27]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[28]  P. Vardas,et al.  Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. , 2000, Chest.

[29]  F. Morady,et al.  Effect of electrode polarity on the energy required for transthoracic atrial defibrillation. , 1999, The American journal of cardiology.

[30]  P. Vardas,et al.  Efficacy of amiodarone for the termination of persistent atrial fibrillation. , 1999, The American journal of cardiology.

[31]  P. Schweitzer,et al.  Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. , 1998, The American journal of cardiology.

[32]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[33]  F. Martin,et al.  Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. , 1997, European heart journal.

[34]  I C van Gelder,et al.  UvA-DARE ( Digital Academic Repository ) Efficacy , safety , and determinants of conversion of atrial fibrillation and flutter with oral amiodarone , 1997 .

[35]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[36]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[37]  P. Sager,et al.  Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. , 1996, Journal of the American College of Cardiology.

[38]  J. Soler‐Soler,et al.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. , 1996, Journal of the American College of Cardiology.

[39]  K. Ellenbogen,et al.  Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. , 1996, Circulation.

[40]  A. Capucci,et al.  Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. , 1995, Chest.

[41]  R. Ganam,et al.  Clinical course of recent-onset atrial fibrillation treated with oral propafenone. , 1994, Chest.

[42]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[43]  H. Crijns,et al.  Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. , 1991, The American journal of cardiology.

[44]  K. Lie,et al.  The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. , 1990, Journal of the American College of Cardiology.

[45]  B B Lerman,et al.  Intrathoracic current flow during transthoracic defibrillation in dogs. Transcardiac current fraction. , 1990, Circulation research.

[46]  R. Boccadamo,et al.  Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. , 1989, The American journal of cardiology.

[47]  M. Brodsky,et al.  Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. , 1989, The American journal of cardiology.

[48]  L. Rydén,et al.  Chronic atrial fibrillation. Long-term results of direct current conversion. , 2009 .

[49]  B. Lown,et al.  Landmark article Nov 3, 1962: New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. By Bernard Lown, Raghavan Amarasingham, and Jose Neuman. , 1986, JAMA.

[50]  E. Williams A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs , 1984 .

[51]  E. V. Vaughan Williams A classification of antiarrhythmic actions reassessed after a decade of new drugs. , 1984, Journal of clinical pharmacology.

[52]  J. Geddes,et al.  The long term prognosis of atrial fibrillation following direct current conversion. , 1968, The Ulster medical journal.

[53]  B. Lown,et al.  New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. , 1986, JAMA.